Immunohistochemical (IHC) techniques are generally thought to be more sensitive as compared to standard histopathology. of micrometastasis in sentinel lymph node. This can have important bearing on deciding the need of adjuvant systemic therapy. A false unfavorable result for EMA may be seen in patients with poorly differential malignancy. Therefore the best policy seems to Glucagon HCl employ both histopathology and IHC for EMA for the comprehensive evaluation of sentinel lymph node in breast malignancy. Keywords:Sentinel node, Breast malignancy, Immunohistochemistry == Introduction == Even several years after the introduction of sentinel lymph node biopsy to reduce the morbidity of axillary lymph node dissection, the best method of pathological examination of the sentinel lymph node has not been agreed upon. The relevance of detection of micrometastasis in the axillary lymph node is also not clear. It is generally accepted that immunohistochemical (IHC) methods are much more sensitive for picking up micrometastasis as compared to standard hematoxilin and eosin (H & E) staining only. Rutgers in his study concluded that omitting IHC for cytokeratin staining was not a capital offence when the pathologist examined a sentinel lymph node [1]. However he also found that once a micrometastasis (i.e. metastasis 0.22.0 mm) is found in the sentinel node, there is Glucagon HCl a Glucagon HCl 1020% chance of involvement of non-sentinel node. Additionally most surgeons advocate axillary lymph node dissection even in the presence of micrometastasis in the sentinel Glucagon HCl node. There are very few studies comparing single section H & E staining with IHC evaluation of the sentinel node for detection of micrometastasis. It is quite likely that the choice of technique could switch the portion of tumor positive lymph nodes, need for adjuvant therapy and ultimately patient prognosis. The aim of our study was to determine whether IHC for Epithelial Membrane Antigen (EMA) around the sentinel node could be more sensitive than standard H & E stain for picking up micrometastasis. == Material & Methods == Over a 3 years period from January 2007 to January 2010, 84 women with breast malignancy visiting the Department of Surgery were recruited for the study. The inclusion criteria were (a) Clinically node unfavorable axilla (b) Not need received pre-operative chemotherapy or radiotherapy (c) Not need undergone a earlier breasts biopsy (d) Neither pregnant or lactating (e) Intraoperative recognition of methylene blue dye stained sentinel node feasible. All individuals were put through customized radical mastectomy (Pateys range) within our regular management process for there individuals. Before operation 5 ml of methylene blue dye was injected peritumorally for staining from the sentinel node. After medical procedures, the blue stained sentinel node was gathered through the mastectomy specimen. The sentinel node was delivered for regular histopathological examination aswell as IHC for EMA. An entire histopathological analysis of most staying axillary nodes gathered through the mastectomy specimen was also completed for relationship. == Approach to IHC for EMA == This is carried out for the paraffin blocks from the sentinel node using regular immunohistochemistry strategies. Prediluted mouse monoclonal antibodies against EMA had been used. The principal antibody clone utilized was E29. The reagents had been procured type Biogenex Existence Sciences Pvt Ltd. (Secunderabad, India). Glucagon HCl == Observations == All 84 breasts cancer ladies recruited with this research had a medically N0 axilla. The common age group was 50.4 years (range 3369 years) with 32 women (38%) being premenopausal and 52 (62%) postmenopausal. According to size the tumors had been categorized as T1= 18 (22%), T2= 49 (58%) and T3= 17 (20%). Intraoperative recognition of blue node was feasible in every 84 individuals recruited with this scholarly research. Of the 69 individuals (82%) got one stained node and 15 individuals (18%) MCMT got 2 stained nodes. The sentinel node was mentioned to become level 1 (inferior compared to pectoralis small tendon) in 72 individuals (85%) and level 2 (behind the pectoralis small tendon) in 12 individuals (15%). On the average.